Cardiology

Top Story

Benefit of ezetimibe/simvastatin for acute coronary syndrome questionable

April 25, 2017

New findings suggest that the trial population of IMPROVE-IT were younger, healthier and received more optimal secondary prevention therapies than current qualifying patients, challenging the use of ezetimibe/simvastatin in patients with acute coronary syndrome, according to a research letter published in JAMA Internal Medicine.

“The recent IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin in patients with recent acute coronary syndrome (ACS) reduced cardiac events by 2% over 7 years, but it is unclear to what degree these results impact clinical care,” Thomas M. Maddox, MD, MSc, from the University of Colorado School of Medicine, and colleagues wrote.

In the Journals

ACC/AHA/HRS guideline provides recommendations for diagnosis, prognosis for syncope

April 25, 2017
The American College of Cardiology, the American Heart Association and Heart Rhythm Society published guidelines for the assessment and treatment of patients with
In the Journals

Physical activity associated with reduced odds of subclinical myocardial damage

April 24, 2017
Physical activity is associated with decreased risk for myocardial damage in high-risk patient groups and may mitigate the association between obesity and myocardial…
In the JournalsPerspective

HEART score to assess patients with chest pain underutilized in EDs

April 24, 2017
Using the History, ECG, Age, Risk factors and initial Troponin, or HEART, score during initial assessment of patients with chest pain is safe; however, physicians did…
In the Journals

Quality-of-life outcomes better with CABG vs. PCI in three-vessel, left main CAD

April 24, 2017
Patients who underwent CABG vs. PCI with a drug-eluting stent had improved angina frequency, physical function, and physical and emotional scores on quality-of-life…
More News Headlines »
Advertisement
Advertisement